Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Genentech’s Cancer Product Line Expands, As Do Its Post-Market Manufacturing Obligations

This article was originally published in RPM Report

Executive Summary

Genentech appears to be having significant manufacturing problems for some of its new cancer therapies. FDA hasn’t taken enforcement action yet, but the agency has delayed two approvals and tied them to post-market requirements to address QC issues.


Related Content

FDA’s “Breakthrough” Evolves: What’s Next For The Popular Program?
Expanded Access Theme Is One Sour Note For Biopharma In “21st Century Cure” Roundtable
Kadcyla Manufacturing Review Was A Production In Itself
Much “Ado” About Biosimilars
Breaking Down the First “Breakthrough”
Genentech’s Perjeta Clears FDA Despite Unresolved Manufacturing Issues
FDA “Flexibility” Presages Good Climate in 2012 for Approval Decisions, Shortage Situations
How to Withdraw a Drug: FDA’s Final Decision on Avastin
Roche and FDA in Oncology: Fighting in Public, Collaboarting in Private


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts